NCT06556368Phase 3Active not recruiting

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Study sponsor: Kodiak Sciences Inc · KOD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09-02Actual
Enrollment · participants667Actual
Source updated2026-11-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 675 participants (planned). After: 667 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2026. After: 2 Sep 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview